Clinical Efficacy and Safety of Tenofovir Disoproxil Fumarate and Entcavir in Treatment of Chronic Hepatitis B Patients in Upper Egypt

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-15

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic hepatitis B (CHB) is one of the major causes of chronic liver diseases worldwide. Around 296 million people were living with chronic hepatitis B infection, with 1.5 million new infections each year and more than 820 thousand people die because of hepatitis B virus (HBV) related complications

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection

NCT03186313

Hepatitis C

COMPLETED PHASE3

Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients

NCT07274345

Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection

NOT_YET_RECRUITING

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

NCT01940471

HBeAg-positive Chronic Hepatitis B

COMPLETED PHASE3

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b

NCT04195074

Chronic Hepatitis b

UNKNOWN NA

A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B

NCT03258710

Hepatitis B, Chronic

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic Hepatitis B is a long-term liver disease. The disease is often characterized by abnormal levels of serum ALT and AST, as well as liver histology, and is transmitted through blood, sexual contact, and mother-to-child transmission.

The symptoms of CHB include fatigue, nausea, abdominal distension, and Rt hypochondrial pain, and in severe cases, it can be accompanied by chronic liver disease, spider nevus, abnormal liver function, or persistent abnormality. The progression of hepatitis B virus (HBV) is closely linked to its replication, and the most effective way to prevent it is through hepatitis B vaccination. However, there is currently no specific drug available to eliminate the virus in patients with chronic hepatitis B (CHB) due to the low rate of HBsAg clearance. Instead, primary treatment methods for CHB aim to inhibit virus replication for an extended period and delay the onset of liver cirrhosis and hepatocellular carcinoma. Antiviral, liver protection, antifibrosis, and immunomodulatory therapies are used to achieve this goal. Among these therapies, nucleoside (acid) analogs (NA) are commonly used, with drugs such as entecavir (ETV) and tenofovir (TDF) being the most effective. Tenofovir is a new type of nucleotide reverse transcriptase inhibitor, which inhibits reverse transcriptase similarly to nucleoside reverse transcriptase inhibitors. To a certain extent, it can reduce transaminase, protect the liver, and has a good effect on the treatment of hepatitis B. ETV is a carboxylic analog of 2'-deoxyguanosine, which inhibits HBV DNA polymerase by competing with natural deoxy guanosine triphosphate.

The use of entecavir (ETV) and tenofovir disoproxil (TDF) are both effective in managing hepatitis B virus (HBV) infection, and are well-tolerated by most patients.

While there are no significant differences in the ability of the various treatments to suppress the virus, some studies suggest that TDF may achieve biochemical response more quickly. Nucleoside analogs with a high barrier to resistance are unlikely to lead to the clearance of hepatitis B surface antigen, and should therefore be continued for most patients throughout their lifetime. However, there are concerns about the potential for toxicity with TDF in patients who have additional risk factors for kidney and bone problems. It is important to monitor for adverse effects, and switching to ETV may be a safe and effective alternative for patients with HBV. Although effective antiviral treatment can improve the clinical outcome of chronic HBV patients, there is still a risk of developing hepatocellular carcinoma (HCC) even with viral suppression. It is unclear whether TDF-based regimens offer any additional benefits over ETV in preventing HCC, and more research is needed in this area. Studies conducted on both TDF and ETV have demonstrated their safety in both pivotal trials and real-life cohorts. In less than 10% of cases, mild side effects such as headache, fatigue, dizziness, nausea, abdominal discomfort, and nasopharyngitis have been reported for both drugs. These side effects are generally temporary and not severe enough to require discontinuation of treatment. However, TDF has been associated with kidney dysfunction, particularly in patients with pre-existing kidney disease or other risk factors for renal impairment. Furthermore, TDF has been linked to bone disease. As a result, the European Association for the Study of the Liver recommends selecting or switching to ETV for patients with chronic hepatitis B who are at greater risk of bone and kidney toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis b Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tenofovir Disoproxil Fumarate and Entcavir

Regular registration of side effects of the drugs, cause of non-compliance to treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with HbsAg positivity for at least 6 months.
* Patients have HbeAg positive or negative.
* Patient recived Theryapy with ETV 0.5 or 1 mg/day or TDF 300 mg/day.
* Patients have Regular monitoring every 6 months.

Exclusion Criteria

* Patients younger than 18 years old.
* Patients co-infected with hepatitis C, hepatitis D.
* Patients receiving immune suppressive therapy or with history of immunodeficiency

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No